137 related articles for article (PubMed ID: 37833463)
1. Treatment Patterns and Outcomes in Pancreatic Cancer: A Comparative Analysis of Ontario and the USA.
Saadat LV; Schofield E; Bai X; Curry M; Saskin R; Lipitz-Snyderman A; Soares KC; Kingham TP; Jarnagin WR; D'Angelica MI; Wright FC; Irish JC; Coburn NG; Wei AC
Ann Surg Oncol; 2024 Jan; 31(1):58-65. PubMed ID: 37833463
[TBL] [Abstract][Full Text] [Related]
2. Trajectory of care and use of multimodality therapy in older patients with pancreatic adenocarcinoma.
Parmar AD; Vargas GM; Tamirisa NP; Sheffield KM; Riall TS
Surgery; 2014 Aug; 156(2):280-9. PubMed ID: 24851723
[TBL] [Abstract][Full Text] [Related]
3. Management and Outcome of Colorectal Cancer Liver Metastases in Elderly Patients: A Population-Based Study.
Booth CM; Nanji S; Wei X; Mackillop WJ
JAMA Oncol; 2015 Nov; 1(8):1111-9. PubMed ID: 26355283
[TBL] [Abstract][Full Text] [Related]
4. Trends in utilization of neoadjuvant therapy and short-term outcomes in resected pancreatic cancer.
Mirkin KA; Hollenbeak CS; Gusani NJ; Wong J
Am J Surg; 2017 Jul; 214(1):80-88. PubMed ID: 27816199
[TBL] [Abstract][Full Text] [Related]
5. End-of-life care for lung cancer patients in the United States and Ontario.
Warren JL; Barbera L; Bremner KE; Yabroff KR; Hoch JS; Barrett MJ; Luo J; Krahn MD
J Natl Cancer Inst; 2011 Jun; 103(11):853-62. PubMed ID: 21593012
[TBL] [Abstract][Full Text] [Related]
6. Nonsurgical therapies for resected and unresected pancreatic cancer in Europe and USA in 2003-2014: a large international population-based study.
Huang L; Jansen L; Balavarca Y; van der Geest L; Lemmens V; Van Eycken L; De Schutter H; Johannesen TB; Primic-Žakelj M; Zadnik V; Mägi M; Pulte D; Schrotz-King P; Brenner H
Int J Cancer; 2018 Dec; 143(12):3227-3239. PubMed ID: 29923613
[TBL] [Abstract][Full Text] [Related]
7. Variation in Diagnosis, Treatment, and Outcome of Esophageal Cancer in a Regionalized Care System in Ontario, Canada.
Habbous S; Yermakhanova O; Forster K; Holloway CMB; Darling G
JAMA Netw Open; 2021 Sep; 4(9):e2126090. PubMed ID: 34546371
[TBL] [Abstract][Full Text] [Related]
8. Nationwide trends and outcomes of neoadjuvant chemotherapy in pancreatic cancer - an analysis of the Swedish national pancreatic cancer registry.
Sternby H; Andersson B
Scand J Gastroenterol; 2022 Nov; 57(11):1361-1366. PubMed ID: 35635264
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant Radiotherapy is Associated With Improved Pathologic Outcomes and Survival in Resected Stage II-III Pancreatic Adenocarcinoma Treated With Multiagent Neoadjuvant Chemotherapy in the Modern Era.
Hue JJ; Dorth J; Sugumar K; Hardacre JM; Ammori JB; Rothermel LD; Saltzman J; Mohamed A; Selfridge JE; Bajor D; Winter JM; Ocuin LM
Am Surg; 2021 Sep; 87(9):1386-1395. PubMed ID: 34382877
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Use of Neoadjuvant Systemic Treatment for Breast Cancer and Short-term Outcomes Before vs During the COVID-19 Era in Ontario, Canada.
Habbous S; Tai X; Beca JM; Arias J; Raphael MJ; Parmar A; Crespo A; Cheung MC; Eisen A; Eskander A; Singh S; Trudeau M; Gavura S; Dai WF; Irish J; Krzyzanowska M; Lapointe-Shaw L; Naipaul R; Peacock S; Yeung L; Forbes L; Chan KKW
JAMA Netw Open; 2022 Aug; 5(8):e2225118. PubMed ID: 35917122
[TBL] [Abstract][Full Text] [Related]
11. The association of adjuvant therapy with survival at the population level following pancreatic adenocarcinoma resection.
Kagedan DJ; Raju RS; Dixon ME; Shin E; Li Q; Liu N; Elmi M; El-Sedfy A; Paszat L; Kiss A; Earle CC; Mittmann N; Coburn NG
HPB (Oxford); 2016 Apr; 18(4):339-47. PubMed ID: 27037203
[TBL] [Abstract][Full Text] [Related]
12. Glottic cancer in Ontario, Canada and the SEER areas of the United States. Do different management philosophies produce different outcome profiles?
Groome PA; O'Sullivan B; Irish JC; Rothwell DM; Math KS; Bissett RJ; Dixon PR; Eapen LJ; Gulavita SP; Hammond JA; Hodson DI; Mackenzie RG; Schneider KM; Warde PR; Mackillop WJ
J Clin Epidemiol; 2001 Mar; 54(3):301-15. PubMed ID: 11223328
[TBL] [Abstract][Full Text] [Related]
13. Association Between Pancreatic Fistula and Long-term Survival in the Era of Neoadjuvant Chemotherapy.
Hank T; Sandini M; Ferrone CR; Rodrigues C; Weniger M; Qadan M; Warshaw AL; Lillemoe KD; Fernández-Del Castillo C
JAMA Surg; 2019 Oct; 154(10):943-951. PubMed ID: 31411659
[TBL] [Abstract][Full Text] [Related]
14. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
[TBL] [Abstract][Full Text] [Related]
15. Differences in receipt of multimodality therapy by race, insurance status, and socioeconomic disadvantage in patients with resected pancreatic cancer.
Hao S; Mitsakos A; Irish W; Tuttle-Newhall JE; Parikh AA; Snyder RA
J Surg Oncol; 2022 Aug; 126(2):302-313. PubMed ID: 35315932
[TBL] [Abstract][Full Text] [Related]
16. Facility volume-survival relationship in patients with early-stage pancreatic adenocarcinoma treated with neoadjuvant chemotherapy followed by pancreatoduodenectomy.
Hue JJ; Sugumar K; Markt SC; Hardacre JM; Ammori JB; Rothermel LD; Winter JM; Ocuin LM
Surgery; 2021 Jul; 170(1):207-214. PubMed ID: 33454134
[TBL] [Abstract][Full Text] [Related]
17. The treatment sequence may matter in patients undergoing pancreatoduodenectomy for early stage pancreatic cancer in the era of modern chemotherapy.
Watson MD; Thompson KJ; Musselwhite LW; Hwang JJ; Baker EH; Martinie JB; Vrochides D; Iannitti DA; Ocuin LM
Am J Surg; 2021 Jul; 222(1):159-166. PubMed ID: 33121658
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant therapy at local versus outside institutions does not adversely impact surgical timing or long-term outcomes in patients with pancreatic adenocarcinoma.
Kim RC; Allen KA; Roch AM; McGuire SP; Ceppa EP; Zyromski NJ; Nakeeb A; House MG; Schmidt CM; Nguyen TK
Surgery; 2023 Mar; 173(3):574-580. PubMed ID: 36253310
[TBL] [Abstract][Full Text] [Related]
19. The Association of Drug-Funding Reimbursement With Survival Outcomes and Use of New Systemic Therapies Among Patients With Advanced Pancreatic Cancer.
Raphael MJ; Raskin W; Habbous S; Tai X; Beca J; Dai WF; Arias J; Forbes L; Gavura S; Biagi JJ; Earle CC; Chan KKW
JAMA Netw Open; 2021 Nov; 4(11):e2133388. PubMed ID: 34779846
[TBL] [Abstract][Full Text] [Related]
20. Multi-agent neoadjuvant chemotherapy improves survival in early-stage pancreatic cancer: A National Cancer Database analysis.
Deng A; Wang C; Cohen SJ; Winter JM; Posey J; Yeo C; Basu Mallick A
Eur J Cancer; 2021 Apr; 147():17-28. PubMed ID: 33607382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
